Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.,The Journal of Urology

当前位置： X-MOL 学术 › J. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-05-17 , DOI: 10.1097/ju.0000000000004010
Louise Emmett _{1,

2,

3} , Nathan Papa ₂ , Thomas A Hope ₄ , Wolfgang Fendler ₅ , Jeremie Calais ₆ , Irene Burger ₇ , Matthias Eiber ₈ , Francesco Barbato ₅ , Daniel Moon ₉ , William Counter ₁ , Nikeith John _{1,

3} , Alan Xue ₁₀ , Anthony Franklin ₁₁ , James Thompson _{2,

12} , Kris Rasiah ₁₃ , Mark Frydenberg ₁₀ , John Yaxley ₁₄ , James Buteau ₁₅ , Shikha Agrawal _{1,

2} , Bao Ho ₁ , Andrew Nguyen ₁ , Victor Liu ₁ , Jonathan Lee ₁ , Henry Woo ₁₆ , Edward Hsiao ₁₆ , Thomas Sutherland ₁₇ , Elyse Perry ₁₇ , Phillip Stricker ₁₂ , Michael S Hofman _{15,

18} , Veeru Kasivisvanathan ₁₉ , Matthew Roberts ₅ , Declan Murphy ₉

Affiliation

Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia.
Garvan Institute of Medical Research, Sydney, Australia.
St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany.
Ahmanson Translational Theranostics, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California, Los Angeles, California.
Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland.
Department of Nuclear Medicine, School of Medicine, Technical University Munich, Munich, Germany.
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Surgery, Faculty of Medicine, Monash University, Melbourne, Victoria, Australia.
Department of Urology, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Department of Urology, St Vincent's Hospital Sydney, Sydney, Australia.
Royal North Shore Hospital, Sydney, Australia.
The Wesley Hospital, Brisbane, Australia.
Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Department of Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer, Melbourne, Australia.
Department of Uro-Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
Department of Radiology, St Vincent's Hospital, Melbourne, Australia.
Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Division of Surgery and Interventional Science, University College London, London, United Kingdom.

The PI-RADS score is standard of care for clinically significant prostate cancer (csPCa) diagnosis. The PRIMARY-score (PSMA-PET/CT) also has high diagnostic accuracy for csPCa. This study aimed to develop an easily calculated combined (P) score for csPCa detection (ISUP ≥ 2) incorporating separately read PI-RADS and PRIMARY scores, with external validation.

中文翻译：

超越 PI-RADS：将 MRI PI-RADS 和 PSMA-PET/CT PRIMARY 评分结合在综合 (P) 评分中，以更准确地诊断有临床意义的前列腺癌。

PI-RADS 评分是具有临床意义的前列腺癌 (csPCa) 诊断的护理标准。 PRIMARY 评分 (PSMA-PET/CT) 对 csPCa 的诊断准确性也很高。本研究旨在开发一种易于计算的 csPCa 检测组合 (P) 评分 (ISUP ≥ 2)，结合单独读取的 PI-RADS 和 PRIMARY 评分，并进行外部验证。

更新日期：2024-05-17

点击分享查看原文

点击收藏

阅读更多本刊新发论文